An observational study in Severe Asthma and Asthma Control Level, sponsored by Thammasat University. Recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Thammasat University · Observational
The goal of this observational study is to determine the prevalence of remission among adults with severe asthma, as well as the factors associated with remission in Thailand.
The main question the study aims to answer is:
What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete questionnaires on asthma symptoms and undergo pulmonary function testing and a blood test once.
This study is a cross-sectional study. Thai patients aged 18 years or older with severe asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC).
4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.
This study's planned enrollment of 230 is above the median of 158 across 1,250 observational studies indexed under Asthma.
Browse Asthma studies →Thammasat University is the lead sponsor of 85 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Thai patients aged 18 years or older with severe asthma are included in the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Asthma that requires treatment with high-dose inhaled corticosteroids plus a second controller, or requires systemic corticosteroids for ≥50% of the previous year to prevent it from becoming uncontrolled, or remains uncontrolled despite this therapy.
Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires · Diagnostic Test: Spirometry · Diagnostic Test: Fractional exhaled nitric oxide (FeNO) test · Diagnostic Test: Blood eosinophil count (BEC)
GINA and ACT are questionnaires used to assess the level of asthma control.
Spirometry is a tool used to assess pulmonary function.
FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.
BEC is a tool used to assess eosinophilic inflammation and asthma remission.
Prevalence rate of severe asthma remission
Prevalence rate of remission in adults with severe asthma
Time frame: The beginning of the study
Association of clinical characteristics with severe asthma remission
The association between severe asthma remission and the following variables will be evaluated: 1. Asthma symptom control; Asthma Control Test (ACT) score (range 5-25) 2. Exacerbation history; Number of asthma exacerbations requiring systemic corticosteroids in the previous 12 months 3. Oral corticosteroid use; Daily oral corticosteroid use (yes/no) and cumulative dose (mg/year) 4. Asthma duration; Years since asthma diagnosis
Time frame: The beginning of the study
Association of lung function with severe asthma remission
The association between severe asthma remission (binary outcome: remission vs. non-remission) and pulmonary function assessed using spirometry (FEV1 % predicted and FEV1/FVC ratio).
Time frame: The beginning of the study
Association of inflammatory biomarkers with severe asthma remission
The association between severe asthma remission (binary outcome: remission vs. non-remission) and inflammatory biomarkers assessed using blood eosinophil count (cells/µL) and fractional exhaled nitric oxide (FeNO) (parts per billion, ppb).
Time frame: The beginning of the study
Plan to share: Yes — IPD and documents
Supporting information: Study protocol, Statistical analysis plan
Time frame: IPD and documents will be available for sharing immediately after publication for a period of 2 years.
Started Jan 2026 (actual). Primary completion is estimated for Oct 2026, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Thammasat University